Aikido Secures Sublicense For Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients

Aikido Pharma Inc (NASDAQ: AIKI) has been granted an exclusive sublicense to technology related to the use of the central nervous system (CNS) homing peptides to treat neuroinflammatory disease in cancer patients.
The homing peptides covered by the sublicense can facilitate the delivery of therapeutic agents to inflamed CNS tissue.
Psychedelics such as psilocybin have been shown to have anti-inflammatory activity in addition to their potential efficacy for the treatment of broad neurological disorders.
The company says that this sublicense culminates the Letter of Intent previously announced on February 16. It also complements recently announced support of the psilocybin research for post-traumatic stress disorder treatment at Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research.
Psilocybin is a hallucinogenic substance from certain types of mushrooms that are also known as magic mushrooms.
Price Action: AIKI shares were trading 1.75% higher at $1.16 in the market trading session on the last check Wednesday.